Monoclonal Antibody A38 Screening for Rift Valley Fever Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no RVF vaccines or neutralizing monoclonal antibodies approved for marketing domestically or globally, and existing laboratory research on monoclonal antibodies targeting RVF virus surface glycoproteins shows limited therapeutic potential.
Innovation Solution
A monoclonal antibody (A38) is developed through immunizing rhesus monkeys, screening with flow cytometry sorting, and sequencing the CDR regions of the heavy and light chains, which are then expressed using an adenovirus vector and human-derived constant regions, demonstrating high binding and neutralizing activity against RVF virus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are developed through traditional laboratory screening methods, then neutralizing activity can be achieved, but the therapeutic potential and binding affinity are limited
Solution Approach 1:
The patent applies preliminary action by pre-immunizing rhesus monkeys with RVF virus antigens to generate high-affinity antibodies before screening. This preparatory immunization process creates a pool of pre-selected antibodies with optimized binding characteristics, which then undergo flow cytometry sorting to identify the highest affinity clones. The preliminary immunization and antibody generation phase ensures that subsequent screening starts with candidates that already possess superior binding potential.
Solution Approach 2:
The patent replaces traditional mechanical screening methods with flow cytometry-based sorting technology. Instead of conventional ELISA or plaque reduction assays, the invention uses flow cytometry to rapidly sort and identify B cells producing antibodies with optimal binding affinity and neutralizing activity. This technological substitution enables high-throughput screening with superior precision in measuring antibody-antigen interactions.
2Adaptability or versatility
If monoclonal antibodies are developed for RVF virus, then therapeutic options can be provided, but no vaccines or neutralizing monoclonal antibodies have been approved for marketing
Solution Approach 1:
The patent applies parameter changes by optimizing multiple critical parameters of the monoclonal antibody including binding affinity (KD < 1 nM), neutralizing activity (IC50 < 1 nM), and protective efficacy in animal models. The invention systematically adjusts immunization protocols, screening criteria, and antibody engineering parameters to achieve a combination of properties that meets or exceeds regulatory approval thresholds. This comprehensive parameter optimization strategy transforms laboratory research candidates into clinically viable therapeutic agents.
3Reliability
If existing monoclonal antibodies targeting Gn and Gc proteins are used, then some protective activity is achieved, but complete protection requires combination therapy
Solution Approach 1:
The patent applies the taking out principle by isolating and optimizing the critical neutralizing function from complex combination therapies. Instead of relying on multiple antibodies working together, the invention identifies and develops a single monoclonal antibody (A38) that extracts and maximizes the essential protective activity against RVF virus. This single antibody demonstrates complete protective efficacy in animal models, eliminating the need for complex combination regimens while maintaining superior reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monoclonal antibody A38 exhibits high binding activity (KD < 1 nM) and neutralizing activity (IC50 < 1 nM), providing complete protection in a lethal mouse model with 20 μg per mouse, and has good stability due to naturally paired genes from rhesus monkeys.
Implementation Method 1
screening with flow cytometry sorting
Data Source
AI summary
Disclosed is a monoclonal antibody against the Rift Valley fever virus. The antibody is screened and obtained by means of flow cytometric sorting and single-cell PCR technology, and has a unique CDR region. Further disclosed is the use of the antibody in the preparation of a drug for treating Rift Valley fever. The monoclonal antibody against the Rift Valley fever virus has high efficiency and specific activity against the Rift Valley fever virus; and also has the characteristics of high expression, high degree of humanization and good stability, and is suitable for industrial production.